US equities |
NVDA $176.69 ▼-5.33% AMD $507.24 ▲+12.96% MU $726.71 ▲+5.32% SPCX $141.59 ▲+5.46% SNDK $882.07 ▲+5.63% AMZN $268.43 ▲+3.52% TSLA $380.51 ▲+6.22% AAPL $351.14 ▲+2.56%
FinancialContent

Evommune, Inc. Common Stock (NY:EVMN)

7.740 +1.090 (+16.39%)
Delayed Quote Updated: 2:53 PM EST, Nov 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Evommune, Inc. Common Stock

News headline image
Evommune to Present at Upcoming Investor Conferences
From Evommune, Inc.
Via Business Wire
News headline image
Evommune Announces Webcast Discussing EVO570 and Its Expanding Immunology Portfolio Today at 8:30 a.m. ET
From Evommune, Inc.
Via Business Wire
News headline image
Evommune Announces $30 Million Private Placement
From Evommune, Inc.
Via Business Wire
News headline image
Evommune Enters into Agreement to In-License EVO570, a Potential Best-in-Class Oral VAV1 Molecular Glue Degrader, from Hinova Pharmaceuticals
From Evommune, Inc.
Via Business Wire
News headline image
Evommune Presents Late-Breaking Phase 2a Proof-of-Concept Data Evaluating EVO301 in Atopic Dermatitis at European Academy of Dermatology and Venereology Congress
From Evommune, Inc.
Via Business Wire
News headline image
Evommune Announces Late-Breaker Presentation of Phase 2a Data for EVO301 in Atopic Dermatitis at European Academy of Dermatology & Venereology 2026 Congress
From Evommune, Inc.
Via Business Wire
News headline image
Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Atopic Dermatitis
From Evommune, Inc.
Via Business Wire
News headline image
Evommune Reports Second Quarter 2026 Financial Results and Provides Business Highlights
From Evommune, Inc.
Via Business Wire
News headline image
Evommune Initiates Phase 2b Clinical Trial of MRGPRX2 Inhibitor EVO756 in Migraine Prophylaxis
From Evommune, Inc.
Via Business Wire
News headline image
Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Chronic Spontaneous Urticaria
From Evommune, Inc.
Via Business Wire
News headline image
Evommune Reports First Quarter 2026 Financial Results and Provides Business Highlights
From Evommune, Inc.
Via Business Wire
News headline image
Evommune to Host KOL Webinar on April 13, 2026 Highlighting the Potential of MRGPRX2 Inhibition in Migraine
From Evommune, Inc.
Via Business Wire
News headline image
Evommune Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights
From Evommune, Inc.
Via Business Wire
News headline image
Evommune Announces $125 Million Private Placement
From Evommune, Inc.
Via Business Wire
News headline image
Evommune Announces Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301 in Moderate-to-Severe Atopic Dermatitis
From Evommune, Inc.
Via Business Wire
News headline image
Evommune Reports Third Quarter 2025 Financial Results and Provides Business Update
From Evommune, Inc.
Via Business Wire